Much research effort in the context of control of cellular signaling responses focuses on protein kinases and the role of protein phosphorylation. The study of CML is no exception. The identification of the Philadelphia chromosome focussed attention on the role of the p210 bcr/abl protein tyrosine kinase. however phosphorylation is a reversible process in vivo and this project will focus on the contribution of the protein tyrosine phosphatases (PTPs). This project offers protein chemical and molecular/cell biological approaches to the study of PTPs with respect to their involvement in CML. The broad, long term objective of these studies is to identify and characterize PTPs as potential antagonists of the aberrant tyrosine phosphorylation associated with the Ph+ CML phenotype. The health relatedness of the project is that through the identification and characterization of PTPs that antagonize the function of p210 bcr/abl, new insights will be provided into the molecular mechanisms underlying CML and new potential targets for therapeutic intervention will be discovered.
The specific aims are as follows: 1. To define the effects of PTP1B on signaling events initiated by p210 bcr/abl. 2. To define the effects of p210 bcr/abl on PTP1B in terms of: a) characterization of the changes in phosphorylation of PTP1B that are observed following expression of p210 bcr/abl; and b) identification nd characterization of potential regulatory proteins that interact with PTP1B in a p210 bcr/abl dependent manner. 3. To test the effects of other PTPs on p210 bcr/abl induced signaling events. 4. To characterize novel PTPs in CML model systems and in human patient samples.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA064593-04
Application #
6237480
Study Section
Project Start
1997-09-15
Project End
1998-05-31
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
4
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Berger, Alice H; Niki, Masaru; Morotti, Alessandro et al. (2010) Identification of DOK genes as lung tumor suppressors. Nat Genet 42:216-23
Rossi, Ferdinand; Yozgat, Yasemin; de Stanchina, Elisa et al. (2010) Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib. Mol Cancer Res 8:1271-83
Guo, Tianhua; Hajdu, Mihai; Agaram, Narasimhan P et al. (2009) Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. Clin Cancer Res 15:6862-70
Antczak, Christophe; Veach, Darren R; Ramirez, Christina N et al. (2009) Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors. Bioorg Med Chem Lett 19:6872-6
Kashiwada, Masaki; Cattoretti, Giorgio; McKeag, Lisa et al. (2006) Downstream of tyrosine kinases-1 and Src homology 2-containing inositol 5'-phosphatase are required for regulation of CD4+CD25+ T cell development. J Immunol 176:3958-65
Liang, Xiquan; Hajivandi, Mahbod; Veach, Darren et al. (2006) Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells. Proteomics 6:4554-64
Janas, Justyna; Skowronski, Jacek; Van Aelst, Linda (2006) Lentiviral delivery of RNAi in hippocampal neurons. Methods Enzymol 406:593-605
Zhao, Mingming; Janas, Justyna A; Niki, Masaru et al. (2006) Dok-1 independently attenuates Ras/mitogen-activated protein kinase and Src/c-myc pathways to inhibit platelet-derived growth factor-induced mitogenesis. Mol Cell Biol 26:2479-89
Oki, Shinji; Limnander, Andre; Yao, Pin Mei et al. (2005) Dok1 and SHIP act as negative regulators of v-Abl-induced pre-B cell transformation, proliferation and Ras/Erk activation. Cell Cycle 4:310-4
Wolff, Nicholas C; Veach, Darren R; Tong, William P et al. (2005) PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. Blood 105:3995-4003

Showing the most recent 10 out of 37 publications